Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
Pfizer nets first AIDS patent in India
Pfizer cleared a big milestone in India today: The company became the first to get patent protection for an AIDS drug there. The new patent covers Celzentry, or maraviroc, a new, first-in-class HIV remedy that was approved by the U.S. FDA in August.
Pfizer's victory follows several other attempts, including GlaxoSmithKline's bid for a patent on Combivir; opposition from patient groups prompted GSK to withdraw its application last year.
- read the report from the Economic Times
- see this chart of HIV drug patent applications and their status in the Business Standard
Related Articles:
Selzentry approval marks big win for Pfizer. Report
Investors yawn at Maraviroc endorsement. Report
New HIV drugs offer breakthrough therapies. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
